Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

ATNM – Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc.
ATNM
$1.36
Name : Actinium Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $42,426,412.00
EPSttm : -1.11
finviz dynamic chart for ATNM
Actinium Pharmaceuticals, Inc.
$1.36
3.55%
$0.05

Float Short %

2.95

Margin Of Safety %

Put/Call OI Ratio

0.01

EPS Next Q Diff

-0.04

EPS Last/This Y

0.19

EPS This/Next Y

0.34

Price

1.37

Target Price

5.75

Analyst Recom

1

Performance Q

-15

Relative Volume

1.08

Beta

-0.3

Ticker: ATNM




20 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-12-02ATNM1.370.010.003174
2025-12-03ATNM1.460.010.003187
2025-12-04ATNM1.450.010.003187
2025-12-05ATNM1.420.010.003197
2025-12-08ATNM1.4150.010.003208
2025-12-09ATNM1.440.010.003238
2025-12-10ATNM1.440.010.003273
2025-12-11ATNM1.4550.010.003253
2025-12-12ATNM1.5050.010.013258
2025-12-15ATNM1.580.010.163227
2025-12-16ATNM1.510.01999.993402
2025-12-17ATNM1.650.010.003413
2025-12-18ATNM1.60.010.003453
2025-12-19ATNM1.70.010.003492
2025-12-22ATNM1.60.020.003273
2025-12-23ATNM1.590.020.003291
2025-12-26ATNM1.50.020.003302
2025-12-29ATNM1.420.020.173294
2025-12-30ATNM1.390.010.003244
2025-12-31ATNM1.370.010.003249
DateSymbolLatestP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-12-02ATNM1.3811.9- -1.08
2025-12-03ATNM1.4511.9- -1.08
2025-12-04ATNM1.4411.9- -1.08
2025-12-05ATNM1.4311.9- -1.08
2025-12-08ATNM1.4011.9- -1.08
2025-12-09ATNM1.4311.9- -1.08
2025-12-10ATNM1.4311.9- -1.08
2025-12-11ATNM1.4511.9- -1.08
2025-12-12ATNM1.5111.9- -1.08
2025-12-15ATNM1.5911.9- -1.08
2025-12-16ATNM1.5911.9- -1.08
2025-12-17ATNM1.6511.9- -1.08
2025-12-18ATNM1.6011.9- -1.08
2025-12-19ATNM1.7011.1- -1.08
2025-12-22ATNM1.6211.1226.5-1.08
2025-12-23ATNM1.6111.1- -1.08
2025-12-26ATNM1.5011.1- -1.08
2025-12-29ATNM1.4211.1- -1.08
2025-12-30ATNM1.3911.1- -1.08
2025-12-31ATNM1.3711.1- -1.08
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-12-02ATNM0.00-1.052.83
2025-12-03ATNM0.00-1.052.83
2025-12-04ATNM0.00-1.052.83
2025-12-05ATNM0.00-1.052.83
2025-12-08ATNM0.0002.83
2025-12-09ATNM0.0002.83
2025-12-10ATNM0.0002.94
2025-12-11ATNM0.0002.94
2025-12-12ATNM0.0002.94
2025-12-15ATNM0.0002.94
2025-12-16ATNM0.0002.94
2025-12-17ATNM0.0002.94
2025-12-18ATNM0.0002.94
2025-12-19ATNM0.0002.94
2025-12-22ATNM0.00-1.052.94
2025-12-23ATNM0.00-1.052.94
2025-12-26ATNM0.00-1.052.95
2025-12-29ATNM0.00-1.052.95
2025-12-30ATNM0.00-1.052.95
2025-12-31ATNM0.00-1.052.95
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

-0.16

Avg. EPS Est. Current Quarter

-0.19

Avg. EPS Est. Next Quarter

-0.2

Insider Transactions

Institutional Transactions

-1.05

Beta

-0.3

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

12

Growth Score

23

Sentiment Score

8

Actual DrawDown %

91

Max Drawdown 5-Year %

-92.6

Target Price

5.75

P/E

Forward P/E

PEG

P/S

471.45

P/B

3.08

P/Free Cash Flow

EPS

-1.11

Average EPS Est. Cur. Y​

-1.08

EPS Next Y. (Est.)

-0.74

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-38443.33

Relative Volume

1.08

Return on Equity vs Sector %

-278.3

Return on Equity vs Industry %

-262.9

EPS 1 7Days Diff

EPS 1 30Days Diff

0.16

EBIT Estimation

Actinium Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 25
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a preclinical non-prostate specific-membrane antigen targeting radiotherapy utilizing the Actinium-225 radioisotope for patients with prostate cancer. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.
stock quote shares ATNM – Actinium Pharmaceuticals Inc Stock Price stock today
news today ATNM – Actinium Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch ATNM – Actinium Pharmaceuticals Inc yahoo finance google finance
stock history ATNM – Actinium Pharmaceuticals Inc invest stock market
stock prices ATNM premarket after hours
ticker ATNM fair value insiders trading